323 related articles for article (PubMed ID: 26067064)
1. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
Rancan C; Schirrmann L; Hüls C; Zeidler R; Moosmann A
PLoS Pathog; 2015 Jun; 11(6):e1004906. PubMed ID: 26067064
[TBL] [Abstract][Full Text] [Related]
2. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
3. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
[TBL] [Abstract][Full Text] [Related]
4. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.
Lin JH; Lin JY; Chou YC; Chen MR; Yeh TH; Lin CW; Lin SJ; Tsai CH
Blood; 2015 Apr; 125(14):2228-38. PubMed ID: 25631773
[TBL] [Abstract][Full Text] [Related]
6. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
7. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
Ikeda M; Ikeda A; Longnecker R
J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
[TBL] [Abstract][Full Text] [Related]
8. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
11. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
[TBL] [Abstract][Full Text] [Related]
12. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
13. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
14. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
16. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
Pender MP; Csurhes PA; Lenarczyk A; Pfluger CM; Burrows SR
J Neurol Neurosurg Psychiatry; 2009 May; 80(5):498-505. PubMed ID: 19015225
[TBL] [Abstract][Full Text] [Related]
17. Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.
Sim AC; Too CT; Oo MZ; Lai J; Eio MY; Song Z; Srinivasan N; Tan DA; Pang SW; Gan SU; Lee KO; Loh TK; Chen J; Chan SH; MacAry PA
Sci Rep; 2013 Nov; 3():3232. PubMed ID: 24240815
[TBL] [Abstract][Full Text] [Related]
18. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
Portis T; Cooper L; Dennis P; Longnecker R
Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
[TBL] [Abstract][Full Text] [Related]
19. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.
Merchant M; Swart R; Katzman RB; Ikeda M; Ikeda A; Longnecker R; Dykstra ML; Pierce SK
Int Rev Immunol; 2001; 20(6):805-35. PubMed ID: 11913951
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]